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Inadequatepreoperative staging,highrates ofincomplete
tumorresection,andearlydistanttumordisseminationmake
the study of adjuvant therapy in pancreatic adenocarcinoma
particularly challenging. To understand the value of che-
moradiation in an adjuvant study, one needs to conﬁrm that
patients accrued to the study have undergone a potentially
curative resection. This is of critical importance because
patients left with a positive surgical margin have a median
survival of less than 12–14 months, a result that may be
achieved bynonsurgical therapies.
1Surprisingly,even high-
volume university-based hospitals report positive surgical
margins as high as 50%.
2,3 The frequency of positive sur-
gical margins is probably much higher in lower-volume
centers. Strict assessments of surgical margins with partic-
ular attention to the retroperitoneal margin (also known as
the SMA margin or uncinate margin) have not been widely
adopted, leading to underreporting of the true margin posi-
tiverateinsomestudies.Furthermore,thecriticaldistinction
between potentially curative (R1) resection and noncurative
gross residual disease (R2 resection) cannot be made
through pathologic examination alone. This was reﬂected in
theRadiationTherapyOncologyGroup(RTOG)97-04trial,
where the surgical margin status for approximately 25% of
enrolled patients was not reported in the operative note or
pathology report, and R1 versus R2 resection status could
not be retrospectively determined.
4 A similar disparity was
observed in the European Study Group for Pancreatic Can-
cer (ESPAC-1) and Charite Onkologie (CONKO-001)
trials.
5,6 Although the proportion of patients having a
positive surgical margin was quite low, local failure rates as
acomponentoffailurewerehigh,rangingfrom35%to62%.
These local failure rates imply that a substantial proportion
of patients receiving adjuvant therapy actually had incom-
plete, noncurative (R2) surgical resections and the
‘‘adjuvant’’ therapy they received after surgery actually
served as treatment for incompletely resected locally
advanced disease.
Subsets of pancreatic cancer patients also have rapid
early tumor dissemination. The frequency of early distant
relapse after pancreatectomy may be extrapolated from
prospective trials of neoadjuvant therapy. Studies from the
University of Texas M. D. Anderson Cancer Center, the
Eastern Cooperative Oncology Group, and Duke Univer-
sity Medical Center have shown that approximately
15–20% of patients with no evidence of distant disease on
initial staging who enroll onto preoperative trials will
develop radiographic evidence of metastatic disease within
several weeks, as documented on their posttreatment pre-
operative restaging computed tomographic scan.
7–9
Because computed tomography was not required before
protocol entry in the early trials that evaluated the role of
radiotherapy, patients undergoing R2 resection or who had
rapidly progressive metastatic disease during the postop-
erative recovery period (15–20% of patients) were not
excluded from protocol entry.
5,10,11 The failure to exclude
these incurable patients from all three early trials evaluat-
ing chemoradiation diluted the statistical power and
confounded the interpretation of the results because the
number of incurable patients may not have been balanced
between the arms.
5,10,11 Even though it is naive to accept
their conclusions at face value, these early trials are con-
sidered the best evidence so far to evaluate the role of
radiotherapy in resected pancreatic cancer, but are they
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III evidence is limited, the value of retrospective evidence
with high surgical and pathologic quality control likely
results in more homogenous group of patients who are
more relevant to assess the beneﬁt of radiotherapy. This
may not be true in other tumor sites where the quality of
the phase III evidence is better.
Evidence in support of the role of chemoradiation has
come from retrospective studies from high-volume centers
of surgical excellence such as the Mayo Clinic and the
Johns Hopkins School (JHU) of Medicine.
12,13 Like all
retrospective single-arm studies, they are all confounded by
selection bias that limits their interpretation and impact.
Nevertheless, the surgical quality, perioperative care, and
expertise in pathologic specimen processing and evaluation
are excellent and help to eliminate those variables as
sources of bias. However, because approximately 40% of
patients in the Mayo series and 30% in the JHU series did
not receive adjuvant chemoradiation, there could be
unidentiﬁed sources of bias that could have confounded the
results. The study by Hsu et al. in this issue of the Annals of
Surgical Oncology reports the pooled data from JHU and
the Mayo Clinic and represents the ﬁrst study that attempts
to control for objective sources of bias using a matched-
pair analysis.
14 This is a large retrospective series that is
well powered for a multivariate analysis. The analysis
identiﬁes younger age, the presence of positive surgical
margins, and high-grade histology as factors associated
with a higher probability of undergoing postoperative
chemoradiation. Some of these factors, such as high-grade
histology and positive surgical margins status, were also
found to be independently associated with an up to 45%
increased the risk of death. A unique strength of this
analysis is the matched pairing, which is arguably the best
attempt to retrospectively control for identiﬁable sources of
selection bias in the delivery of adjuvant therapy in pan-
creatic cancer. With a large sample size (248 patients in
each group), the authors were able to control for several
objective variables in patient selection. Factors that were
statistically signiﬁcant on multivariate analysis (age, stage,
differentiation, margin status, and nodal status) were mat-
ched between the treatment groups. However, as the
authors point out, it was not possible from their data to
control for clinical sources of bias such as performance
status, poor nutritional status, prolonged postoperative
recovery, and medical comorbidites. Declining perfor-
mance status in particular may be a speciﬁc early clinical
indicator of the onset or progression of radiographically
occult metastatic disease. Astute clinicians would not
generally recommend initiation of chemoradiation to
patients who are in a state of clinical decline; this phe-
nomenon in particular could have confounded the ﬁndings
of the analysis.
The development of more effective systemic therapies is
critical to improving surgical outcomes. However, the
accumulated data clearly demonstrate local control as
necessary for long-term survival. Thus, our ability to detect
a beneﬁt from therapies delivered in future clinical trials
depends on our ability to select patients in whom the nat-
ural history of their disease can be altered. This is limited
to patients undergoing a strictly assessed R0 resection who
do not have metastatic disease at the time of protocol entry.
Steps in this direction have been made in the more recent
trials. The CONKO-1 and RTOG 97-04 trials both required
postoperative preenrollment computed tomographic scans
and excluded patients with clear evidence of residual local
tumor or distant metastases.
6,15 The results support the use
of gemcitabine after pancreatectomy as a standard and have
made an impact on clinical practice today.
It is impossible from phase III trials to ascertain what
value, if any, radiotherapy adds to the treatment of
appropriately selected patients who have undergone R0
pancreatic resection. One of the strengths of the current
study is uniform surgical quality. On the other hand, even
though the authors controlled for known prognostic factors
in the analysis, potentially adverse prognostic factors such
as declining performance status could not be controlled for.
Even more homogeneous populations can be accrued with
adherence to standardized deﬁnitions of resectability on the
basis of high-quality preoperative radiographic imaging,
accurate pathologic specimen processing, and surgical
quality control. Effective quality control is extraordinarily
challenging, particularly in the context of adjuvant trials
where patients are traditionally enrolled weeks after the
surgery and pathologic analysis has already been com-
pleted. The ESPAC-3 and European Organization for the
Research and Treatment of Cancer (EORTC) 40013 post-
operative trials both mandated the acquisition of high-
quality preoperative imaging, but did not require adherence
to a standardized deﬁnition of resectability. Prospective
surgical, pathologic, and radiotherapy quality assurance are
planned in the RTOG/EORTC/Intergroup 0848 postoper-
ative adjuvant trial. Surgeons will be required to have
documented total gross excision of the tumor, and the
status of all relevant surgical margins will need to be
reported as part of the inclusion criteria. Preoperative
imaging will be reviewed but not used as part of the
inclusion criteria. Prospective radiographic, surgical, and
pathologic quality control are also planned in the American
College of Surgeons Oncology Group neoadjuvant trial,
Z5041. This trial includes protocol-speciﬁed central
imaging review of pretreatment and preoperative imaging,
protocol-deﬁned surgical technique, standardized assess-
ment of the pathology specimen, and templated pathology
reporting. Deviations are communicated back to the par-
ticipating surgeon. These quality assurance efforts require a
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research staff, but the beneﬁts could go beyond the accu-
racy of interpretation of future trials. For instance,
conﬁdential verbal or written feedback could be informa-
tive enough to inﬂuence practice standards among the
participants. This may ultimately have a greater impact on
patient survival than any speciﬁc adjuvant therapy.
Should this study change practice? This study may lead
the group of clinicians who never recommend chemoradi-
ation because of an underappreciation of the ﬂaws of the
completed phase III trials to reconsider the selected use of
chemoradiation, especially after a period of chemotherapy.
This strategy is reﬂected in the design of RTOG/EORTC/
Intergroup 0848, which includes gemcitabine-based che-
motherapy to all patients for ﬁve cycles, followed by
restaging and subsequent 1:1 randomization to chemora-
diation or one additional cycle of chemotherapy. Outside
enrollment in such a clinical trial, initial treatment should
be systemic gemcitabine for 4 to 6 months followed by
restaging and consideration of ﬂuorouracil-based chemo-
radiation, particularly for patients with close or
microscopically positive retroperitoneal margins.
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